Ascendis Pharma A/S
ASND
$191.12
-$4.86-2.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.10M | -99.58M | -41.01M | -109.06M | -117.73M |
| Total Depreciation and Amortization | 4.89M | 4.78M | 4.27M | 4.81M | 4.72M |
| Total Amortization of Deferred Charges | -- | -- | 497.80K | -- | -- |
| Total Other Non-Cash Items | 80.55M | 26.88M | 65.20M | -47.33M | 63.86M |
| Change in Net Operating Assets | -49.67M | 52.86M | -121.89M | 89.87M | -16.84M |
| Cash from Operations | -8.33M | -15.06M | -92.93M | -61.71M | -65.99M |
| Capital Expenditure | -4.92M | -739.80K | -446.60K | -513.40K | -368.10K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 1.02M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 37.30K | -39.60K | 0.00 |
| Cash from Investing | -4.92M | -739.80K | -409.30K | -553.00K | 654.40K |
| Total Debt Issued | -- | -- | 0.00 | 134.16M | -- |
| Total Debt Repaid | -5.49M | -3.07M | -2.95M | -2.81M | -2.82M |
| Issuance of Common Stock | 12.47M | 13.83M | 22.33M | 296.53M | 365.00K |
| Repurchase of Common Stock | 0.00 | -28.79M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -19.29M | -- | -- |
| Cash from Financing | 7.92M | -18.97M | 92.70K | 470.39M | -2.64M |
| Foreign Exchange rate Adjustments | -21.77M | -9.03M | 22.92M | -4.86M | 1.74M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.10M | -43.80M | -70.32M | 403.27M | -66.24M |